.png)
Search
Displaying 41–50 of 1181 results
-
Early clinical trial results show vision gains in patients with BEST1-related disease
Research NewsOpus Genetics looks ahead to a Phase 3 trial for its potential gene therapy OPGx-BEST1
-
PRPH2 Workshop 2026: Recordings & Presentations
The PRPH2 2026 Workshop continues to bring awareness and build community across PRPH2-related retinal disease and accelerate research on biological and therapeutic approaches.
-
Protect Vision Research Funding
Advocacy Foundation NewsJoin us in the movement to protect vision research funding by reaching out to your members of Congress.
-
A short email copy template that can be used to advocate for the protection of Vision Research Funding.
-
A short phone script that can be used to advocate for the protection of Vision Research Funding.
-
Every voice strengthens our movement. By joining our advocacy network, you’ll receive updates on the latest policy developments, alerts when action is needed, and stories of impact from advocates nationwide. Together, we can shape policies that accelerate treatment and cures, and improve the lives of millions living with blinding diseases.
-
The Foundation Fighting Blindness Advocacy in Focus highlights how we bring our mission into the policy arena, shaping decisions and empowering our community to create lasting change.
-
Usher Syndrome Patient Focused Drug Development Meeting
The goal of the meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with Usher syndrom, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
Beacon's emerging XLRP gene therapy improves low-light vision in phase 3 trial
Research NewsBeacon plans to begin a rolling FDA submission for laru-zova later this year
-
Nanoscope’s investigational RP treatment MOGENRY advances toward FDA approval
Research NewsOne-time injection could treat RP patients regardless of underlying genetic mutation
